Hostname: page-component-8448b6f56d-m8qmq Total loading time: 0 Render date: 2024-04-19T01:49:59.625Z Has data issue: false hasContentIssue false
  • English
  • Français

Legal Enforcement of Xenotransplantation Public Health Safeguards

Published online by Cambridge University Press:  01 January 2021

Patrik S. Florencio  and
Erik D. Ramanathan
Get access Rights & Permissions [Opens in a new window]

Extract

Xenotransplantation is any transplantation, implantation, or infusion of either live cells, tissues, or organs from a nonhuman animal source, or human bodily fluids, cells, tissues, or organs that have had ex vivo contact with live nonhuman animal cells, tissues, or organs into a human recipient. Most scientists agree that clinical xenotransplantation should not be performed in the absence of accompanying public health safeguards The science upon which that consensus is based has been extensively described in the literature. By and large the most compelling reason for public health safeguards is the possible introduction of new infectious agents into the human life cycle as a result of xenotransplantation.

The most frequent source of new infectious diseases in human populations is the transfer of agents, such as viruses, bacteria, or prions, from animals to man. Human diseases and infectious agents that are thought to have originated from animals include influenza, rabies, malaria, lassa fever, lyme disease, AIDS, yellow fever, tuberculosis, the human t-cell lymphotropic virus, the herpes B virus, the hantavirus, and even the bubonic and pneumonic plagues.

Type
Article
Information
Journal of Law, Medicine & Ethics , Volume 32 , Issue 1 , Spring 2004 , pp. 117 - 123
Copyright
Copyright © American Society of Law, Medicine and Ethics 2004

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

U.S. Food and Drug Administration, PHS Guideline on Infectious Disease Issues in Xenotransplantation, at <http://www.fda.gov/cber/gdlns/xenophs0101.htm> (last visited January 21, 2004).+(last+visited+January+21,+2004).>Google Scholar
Chapman, L.E. et al. , “Xenotransplantation and Xenogeneic Infections,” N. Engl. J. Med. 333 (1995): 1498–1501;Murphy, F.A., “The Public Health Risk of Animal Organ and Tissue Transplantation Into Humans,”Science 273 (1996): 746–47; Allan, J.S., “Xenotransplantation at a Crossroads: Prevention Versus Progress,”Nature Medicine 2 (1996): 18–21;Fishman, J.A., “Infection and Xenotransplantation: Developing Strategies to Minimize Risk,” Annals of the New York Academy of Sciences 862 (1998): 52–65;Weiss, R.A., “Xenografts and Retroviruses,”Science 285 (1999): 1221–22;Allen, J.S., “Understanding Xenotransplantation Risks from Nonhuman Primate Retroviruses,” Current Topics in Microbiology and Immunology 278 (2003): 101–123.CrossRefGoogle Scholar
Id. See also, Butler, D., “Last Chance to Stop and Think on Risks of Xenotransplantation,” Nature 391 (1998): 320–24;Chapman, L.E. Bloom, E.T., “Clinical Xenotransplantation,”JAMA 285 (2001): 2304–06.The public health risks associated with xenotransplantation are also reviewed in Florencio, P.S. Ramanathan, E.D., “Are Xenotransplantation Safeguards Legally Viable?,” Berkeley Technology Law Journal 16: Suppl. (2001): 937–77.Google Scholar
Morse, S.S. Schluederberg, A., “Emerging Viruses: The Evolution of Viruses and Viral Diseases,” Journal of Infectious Diseases 264 (1990): 1–7;Gibbons, A., “Where are New Diseases Born?,”Science 261 (1993): 68–70.CrossRefGoogle Scholar
Taubenberger, J.K. et al. , “Initial Genetic Characterization of the 1918 Spanish’ Influenza Virus,” Science 275 (1997): 1793–96.CrossRefGoogle Scholar
Baer, G.M. Tordo, N., “Rabies Virus,” in Webster, R.G. Granoff, A., eds., Encyclopedia of Virology(San Diego: Academic Press, 1994): 1180–85.Google Scholar
Nikiforuk, A., The Fourth Horseman: A Short History of Plagues, Scourges and Emerging Viruses (Toronto: Penguin Books, 1996): at 27.Google Scholar
Holmes, G.P. et al. , “Lassa Fever in the United States: Investigation of a New Case and Guidelines for Management,” N. Engl. J. Med. 323 (1990): 1120–23;Suresh, V., “The Enigmatic Haemorrhagic Fevers,” Journal of the Royal Society of Medicine 90 (1997): 622 –24.CrossRefGoogle Scholar
Levine, J.F. Wilson, M.L. Spielman, A., “Mice as Reservoirs of the Lyme Disease Spirochete,” American Journal of Tropical Medical Hygiene 34 (1985): 355–60;Matuschka, F.R. et al. , “Capacity of European Animals as Reservoir Hosts for the Lyme Disease Spirochete,” Journal of Infectious Diseases 165 (1992): 479–83;Kaiser, J., “Of Mice and Moths — and Lyme Disease?,” Science 279 (1998): 984–85.CrossRefGoogle Scholar
Franchini, G. Bosch, M.L., “Genetic Relatedness of the Human Immunodeficiency Viruses Type 1 and 2 (HTV-1, HIV-2) and the Simian Immunodeficiency Virus (SIV),” Annals of the NY Academy of Sciences 554 (1989): 81–87;Gao, F. et al. , “Human Infection by Genetically Diverse SIVSM-related HIV-2 in West Africa,” Nature 358 (1992): 495–99.CrossRefGoogle Scholar
Oldstone, M.B.A., Viruses, Plagues, and History (New York: Oxford University Press, 1998): at 46.Google Scholar
Stead, W.W., “The Origin and Erratic Global Spread of Tuberculosis: How the Past Explains the Present and is the Key to the Future,” Clinical Chest Medicine 18, no. 1 (1997): 65–77.CrossRefGoogle Scholar
Poiesz, B.J. et al. , “Detection of Type C Retrovirus Particles From Fresh and Cultured Lymphocytes of a Patient with T-Cell Lymphoma,” Proceedings of the National Academy of Sciences U.S.A. 77 (1980): 7415–19;Koralnik, I.J. et al. , “Phylogenetic Associations of Human and Simian T-Cell Leukemia/Lymphotropic Virus Type 1 Strains: Evidence For Interspecies Transmission,” Journal of Virology 68 (1994): 2693–2707.CrossRefGoogle Scholar
Chapman, , supra note 2, at 1499.Google Scholar
Hughes, J.M. et al. , “Hantavirus Pulmonary Syndrome: An Emerging Infectious Disease,” Science 262 (1993): 850–51;Morse, S.S., Emerging Viruses (New York: Oxford University Press, 1993).CrossRefGoogle Scholar
McNeill, W.H., Plagues and Peoples (New York: Anchor Press, 1976);Mims, C.A., “The Origin of Major Human Infections and the Crucial Role of Person-to-Person Spread,” Epidemiology & Infection 106 (1991): 423–33.Google Scholar
McClure, M.A. et al. , “Sequence Comparisons of Retroviral Proteins: Relative Rates of Change and General Phylogeny,” Proceedings of the National Academy of Sciences U.S.A. 85 (1988): 2469–73.CrossRefGoogle Scholar
Scholtissek, C. Rohde, W. von Hoyningen, V. et al. , “On the Origin of the Human Influenza Virus Subtypes H2N2 and H3N3,” Virology 87 (1978): 13–20.CrossRefGoogle Scholar
U.S. Food and Drug Administration, PHS Guideline on Infectious Disease Issues in Xenotransplantation, at <http://www.fda.gov/cber/gdlns/xenophs0101.htm> (last visited January 21, 2004); Health Canada, Proposed Canadian Standard for Xenotransplantation, at <http://www.hc-sc.gc.ca/hpb-dgps/therapeut/zfiles/english/bgtd/xeno_std_e.html> (last visited January 21, 2004);United Kingdom Xenotransplantation Interim Regulatory Authority (UKXIRA), Draft Report of the Infection Surveillance Steering Group of the UKXIRA, at <http://www.doh.gov.uk/pub/docs/doh/surveil.pdf> (last visited January 21, 2004).+(last+visited+January+21,+2004);+Health+Canada,+Proposed+Canadian+Standard+for+Xenotransplantation,+at++(last+visited+January+21,+2004);United+Kingdom+Xenotransplantation+Interim+Regulatory+Authority+(UKXIRA),+Draft+Report+of+the+Infection+Surveillance+Steering+Group+of+the+UKXIRA,+at++(last+visited+January+21,+2004).>Google Scholar
Solomon, D.R. Ferguson, R.M. Helderman, J.H., “Xenotransplants: Proceed With Caution,” Nature 392 (1998): 11;Starlz, T.E. et al. , “Will Xenotransplantation Ever Be Feasible?,” Journal of the American College of Surgeons 186 (1998): 383;Sachs, D.H. et al. , “Xenotransplantation — Caution, But No Moratorium,” Nature Medicine 4 (1998): 372; Boch, X., “Spanish Researchers Reject Xeno Moratorium,” Nature Medicine 5 (1999): 361;Vogel, G., “No Moratorium on Clinical Trials,” Science 279 (1998): 648.CrossRefGoogle Scholar
Gould, S.J., Rocks of Ages: Science and Religion in the Fullness of Life (New York: The Library of Contemporary Thought, 1999): at5–6.Google Scholar
Florencio, P.S. Caulfield, T, “Xenotransplantation and Public Health: Identifying the Legal Issues,” Canadian Journal of Public Health 90 (1999): 282–84;Caulfield, T.A. Robertson, G.B., “Xenotransplantation: Consent, Public Health and Charter Issues,” Medical Law International 5 (2001): 81–99.CrossRefGoogle Scholar
Daar, A.S., “Ethics of Xenotransplantation: Animal Issues, Consent, and Likely Transformation of Transplant Ethics,” World Journal of Surgery 21 (1997): 975–82;Bach, F. et al. , “Uncertainty in Xenotransplantation: Individual Benefit Versus Collective Risk,” Nature Medicine 4 (1998)141–44;Cooper, D.K.C. Lanza, R.P., Xeno: The Promise of Transplanting Animal Organs Into Humans (New York: Oxford University Press, 2000): at 218.CrossRefGoogle Scholar
Supra note 1.Google Scholar
Id.Google Scholar
Id.Google Scholar
Id.Google Scholar
Florencio, Ramanathan, , supra note 3.Google Scholar
Beauchamp, T.L. Childress, J.F., Principles of Biomedical Ethics, 4th ed. (New York: Oxford University Press, 1994): at 120;Picard, E.I. Robertson, G.B., Legal Liability of Doctors and Hospitals in Canada, 3rd ed. (Scarborough: Carswell, 1996): at 11O.Google Scholar
Ciarlariello v. Schacter [1993] 2 S.C.R. 119 (Can.); Reihl v. Hughes [1980] 2 S.C.R. 880 (Can.); Salgo v. Leland Stanford Jr. University Board of Trustees, 317 P.2d 170 (Cal. 1957); Canterbury v. Spence, 464 F.2d 772 (D.C. Cir. 1972).Google Scholar
Malette v. Shulman [Ont. Ct. App. 1990] 67 D.L.R. (4th) 321 (Can.);Nancy B v. Hotel-Dieu de Quèbec [Que. Sup. Ct. 1992] 86 D.L.R. (4th) 385 (Can.); Cruzan v. Director, Missouri Dept. of Health, 497 U.S. 261 (1990).Google Scholar
Daar, , supra note 23;Bach, et al. ., supra note 23;Cooper, Lanza, , supra note 23.Google Scholar
Fitzpatrick v. Micheal, 9 A.2d 639 Md. (1939);American Broadcasting Companies, Inc. v. Warner Wolf, 420 N.E.2d 363 (N.Y. 1981).Google Scholar
Warner Bros. Pictures Inc. v. Nelson [1937] 1 K.B. 209 (Can.);Emerald Resources Ltd. v. Sterling Oil Properties Management Ltd. [Alberta Ct. App. 1969] 3 D.L.R. (3d) 630, 647 (Can.), aff’d, [1970] 15 D.L.R. (3d) 256 (Can.).Google Scholar
For additional reasoning on this point, see Florencio, Ramanathan, , supra note 3, at 949–53.Google Scholar
Canadian Charter of Rights and Freedoms, Part I of the Constitution Act, 1982, being Schedule B to the Canada Act 1982 (U.K.), 1982, c. 11, s. 7;U.S. Constitution, Amendment XIII; Universal Declaration of Human Rights, Art. III, U.N. Res. 217A (III) (1948).Google Scholar
Health Protection and Promotion Act, R.S.O. ch. H-7, § 22(2) (1990) (Can.); Cal. Health and Safety Code § 120175 (West 2000).Google Scholar
Model State Emergency Health Powers Act (2001), available at <http://www.publichealthlaw.net/MSEHPA/MSEHPA2.pdf> (last visited July 24, 2002).+(last+visited+July+24,+2002).>Google Scholar
Id. at § 502 (a).Google Scholar
Id. at § 301.Google Scholar
Florencio, Ramanathan, , supra note 3.Google Scholar
Dunbar-Jacob, J. et al. , “Adherence in Chronic Disease,” Annual Review of Nursing Research 18 (2000): 48–90.CrossRefGoogle Scholar
Laederach-Hofmann, K. et al. , “Noncompliance in Organ Transplant Recipients: A Literature Review,” General Hospital Psychiatry 22, no. 6 (2000): 412–24.CrossRefGoogle Scholar
Ball, C.A. Barnes, M., “Public Health and Individual Rights: Tuberculosis Control and Detention Procedures in New York City,” Yale Law & Policy Review 12, no. 1 (1994): 38–67.Google Scholar
45 C.F.R. § 46.1l6(a)(8) (2001); 21 C.F.R. § 50.26(8) (2001).Google Scholar
Regarding the need for federal legislation, see Florencio, Ramanathan, , supra note 3 at 953–63.Google Scholar
United States v. Estate of Romani, 523 U.S. 517 (1998).Google Scholar
Canadian Charter of Rights and Freedoms ch. 11, §§ 7-& 8 U.S. Constitution, Amendment IV (the “Search and Seizure Clause”); U.S. Constitution, Amendment XIV (the “Due Process Clause”).Google Scholar
Canadian Charter of Rights and Freedoms, ch. 11, § 15; U.S. Constitution, Amendment XIV (the “Equal Protection Clause”).Google Scholar
Florencio, Ramanathan, , supra note 3, at 963–75.Google Scholar
Id.Google Scholar
Id.Google Scholar
Bach, et al. , supra note 23; Somerville, M., The Ethical Canary: Science, Society and the Human Spirit (Toronto: Penguin, 2000): at 104.Google Scholar
In addition to the issue of how to assure that societal consent is informed, other issues needing further erudition include how to effectively disseminate information to the public (e.g., mailed information packages, televised debate); how to collect consent (e.g., referendum, online polls); quorum requirement — what percentage of a nation’s citizenry must vote for the societal consent or refusal to be considered effective and binding (e.g., 15%; 30%; 50%); level of consent required (e.g., regular majority; two thirds majority); scope of the research to which consent is being provided (e.g., cell and tissue xenotransplantation, whole organ xenotransplantation); effect of societal refusal (i.e., particularly in countries already engaged in clinical trials of cell and tissue xenotransplantation).Google Scholar
Defoe, D., A Journal of the Plague Year (Oxford: Oxford University Press, 1990): At 35–36.Google Scholar